The ESMO Precision Medicine Working Group recommends that multigene NGS panel testing replace single‐gene assays and be considered for patients with metastatic prostate cancer, and those with pathogenic or likely pathogenic mutations in cancer‐risk genes should be referred for genetic counselling and germline testing for BRCA1/BRCA2 and other HRR alterations [42]. This evidence concerns the gene BRCA1 and cancer.